Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | Learnings from a CAR-T center: leukapheresis, bridging therapy, toxicities & more

Michael von Bergwelt • 15 Mar 2019
ISAL 2019
General Leukemia Lymphoma CAR-T Tocilizumab

Michael von Bergwelt, MD, PhD, of LMU Hospital Munich, Munich, Germany, discusses the considerations when giving CAR-T in the clinic, including reimbursement, preparing the patient, determining a bridging therapy, toxicity control and more. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Michael von Bergwelt

Increase in cancer patient transfers to the ICU: what does it come down to? 2:25
Increase in cancer patient transfers to the ICU: what does it come down to?
Michael von Bergwelt • 10 Jul 2019
EuroCARTForce: a platform for progress 2:33
EuroCARTForce: a platform for progress
Michael von Bergwelt • 10 Jul 2019
Preparing the critical care workforce for CAR-T 1:14
Preparing the critical care workforce for CAR-T
Michael von Bergwelt • 10 Jul 2019
Intensive care for CAR-T: bridge to treatment and response 2:30
Intensive care for CAR-T: bridge to treatment and response
Michael von Bergwelt • 15 Mar 2019

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals